PRFX is trading 5% down today at $1.52 as investors lock in profits following a sharp rally driven by positive data for its lead pain candidate, PRF-110.
- The stock is retracing a portion of Thursday’s 13.48% surge as market enthusiasm around the preclinical pain-management results normalizes.
- No new company-specific developments have been reported so far today to sustain the previous session's upward momentum.